Current Practices in Safety Pharmacology

Preclinical Development Handbook: Toxicology

Volumn , Issue , 2007, Pages 611-694

  Bass, Alan S ^a   Siegl, Peter K S ^a   Gintant, Gary A ^b   Murphy, Dennis J ^c   Porsolt, Roger D ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ABBOTT LABORATORIES   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Porsolt and Partners Pharmacology   (France)

Author keywords

Cardiac ventricular repolarization; Central nervous system (CNS); Discrete blood level sampling

Indexed keywords

EID: 51649109946     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249055.ch18     Document Type: Chapter

References (243)

1. Zbinden G. Pharmacological Methods in Toxicology. Elmsford, NY: Pergamon Press; 1979.
2. Bass AS, Kinter L, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 2004; 49: 145-151.
3. Anon. Guidelines for General Pharmacology Studies. Tokyo, Japan: Ministry of Health and Welfare; 1991.
4. Anon. General Pharmacology Japanese Guidelines for Nonclinical Studies of Drugs Manual, Tokyo, Japan: Yakuji Nippo Limited; 1995.
5. Shah RR. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 2004; 36 (Suppl 1): 47-52.
6. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. Multicenter Study JAMA 2000; 283: 1703-1709.
7. Anon. ICH Guidance for Industry - S7A Safety Pharmacology Studies for Human Pharmaceuticals. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2001.
8. Bass AS, Tomaselli G, Bullingham R III, Kinter LB. Drug effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 2005; 52: 12-21.
9. Kinter LB, Siegl PK, Bass AS. New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age. J Pharmacol Toxicol Methods 2004; 49: 153-158.
10. Baillie M, Bass AB, Darpo B, Engwall M, Garnes D, Gintant G, Hammond T, Hanson LA, Mittelstadt S, Rampe D, Sarazan RD, Siegl P, Thomas K. International Life Sciences Institute/Health & Environmental Sciences Institute Cardiovascular Risk Assessment, Cardiovascular Risk Assessment Workshop Proceedings; 2007.
11. Anon. ICH Guidance for Industry - S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2005.
12. Harrison AP, Erlwanger KH, Elbrond VS, Andersen NK, Unmack MA. Gastrointestinal- tract models and techniques for use in safety pharmacology. J Pharmacol Toxicol Methods 2004; 49: 187-99.
13. Kinter LB. Safety pharmacology of the renal and gastro-intestinal systems. In: Williams PD, Bass AS, Eds. Safety Pharmacology: A Practical Guide. Gaithersburg, MD: TherImmune Research Corporation; 2003.
14. Gray LE. Jr, Kelce WR, Wiese T, Tyl R, Gaido K, Cook J, Klinefelter G, Desaulniers D, Wilson E, Zacharewski T, Waller C, Foster P, Laskey J, Reel J, Giesy J, Laws S, McLachlan J, Breslin W, Cooper R, Di Giulio R, Johnson R, Purdy R, Mihaich E, Safe S, Sonnenschein C, Welshons W, Miller R, McMaster S, C olborn T. Endocrine Screening Methods Workshop report: detection of estrogenic and androgenic hormonal and antihormonal activity for chemicals that act via receptor or steroidogenic enzyme mechanisms . Reprod Toxicol 1997; 11: 719-750.
15. Emeigh Hart SG. Assessment of renal injury in vivo. J Pharmacol Toxicol Methods 2005; 52: 30-45.
16. Descotes J. Developments in biological standardization. Immunotoxicol Immunomodulators 1992; 77: 99-102.
17. Whitebread S, Hamon J, Bojanic D, Urban L. In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005; 10: 1421-1433.
18. Friedrichs GS, Patmore L, Bass AS. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods 2005; 52: 6-11.
19. Kinter LB, Valentin JP. Safety pharmacology and risk assessment. Fundam Clin Pharmacol 2002; 16: 175-182.
20. Matsuzawa T, Hashimoto M, Nara H, Yoshida M, Tamura S, Igarashi T. Current status of conducting function tests in repeated dose toxicity studies in Japan. J Toxicol Sci 1997; 22: 375-382.
21. Gad SC. Safety Pharmacology in Pharmaceutical Development and Approval. Boca Raton, FL: CRC Press; 2004.
22. Bass AS, Darpo B, Breidenbach A, Bruse K, Feldman HS, Garnes D, Hammond T, Haverkamp W, January C, Koerner J, Lawrence C, Leishman D, Roden D, Valentin JP, Vos MA, Zhou YY, Thomas K, Sager P. Recommendations for areas of investigation from the Workshop Breakout Sessions. Workshop: Moving Towards Better Predictors of Drug-Induced Torsades de Pointes (TdP); 2005.
23. Anon. ICH Guidance for Industry - S6 Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 1997.
24. Anon. ICH Guidance for Industry - M3 NonClin Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 1997.
25. Anon. Title 21 Code of Federal Regulations (21 CFR Part 58). Good Laboratory Practice for NonClinical Laboratory Studies. Washington, DC: US Department of Health and Human Service, Food and Drug Administration; revised 1 April 2006.
26. Anon. ICH Guidance for Industry - E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2005.
27. Anon. Title 21 Code of Federal Regulations (21 CFR Part 11). Electronic Records; Electronic Signatures. Washington, DC: US Department of Health and Human Service, Food and Drug Administration, 2000.
28. Wakefield ID, Pollard C, Redfern WS, Hammond TG, Valentin JP. The application of i n vitro methods to safety pharmacology. Rev Fundam Clin Pharmacol 2002; 16: 209-218.
29. Suter W. Predictive value of in vitro safety studies. Curr Opin in Chem Biol 2006; 10: 362-366.
30. Ollerstam A, Visser SA, Persson AH, Eklund G, Nilsson LB, Forsberg T, Wiklund SJ, Gabrielsson J, Duker G, Al-Saffar A. Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. J Pharmacol Toxicol Methods 2006; 53: 174-183.
31. Sheiner LB, Steimer JL. PharmacokInetic/pharmacodynamic ModelIng In drug development . Annu Rev Pharmacol Toxicol 2000; 40: 67-95.
32. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clin models of QT prolongation. J Pharmacol Toxicol Methods. 2006; 54: 116-129.
33. Klumpp A, Trautmann T, Markert M, Guth B. Optimizing the experimental environment for dog telemetry studies. J Pharmacol Toxicol Methods 2006; 54: 141-149.
34. Chaves AA, Keller WJ, O'Sullivan S, Williams MA, Fitzgerald LE, McPherson HE, Goykhman D, Ward PD, Hoe CM, Mixson L, Briscoe RJ. Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. J Pharmacol Toxicol Methods 2006; 54: 150-158.
35. Swissa M, Zhou S, Paz O, Fishbein MC, Chen LS, Chen PS. Canine model of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia. Am J Physiol Heart Circ Physiol 2005; 289: H1851-H1857.
36. Acosta D Jr, Ed. Cardiovascular Toxicology. London: Taylor & Francis; 2001.
37. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006.
38. Berne RM, Levy MN. Cardiovascular Physiology, 8th ed. St Louis, MO: Mosby; 2001.
39. De Mello WC, Janse MJ. Heart cell coupling and impulse propogation [sic] in health and disease. Boston: Kluwer Academic Pubulishers; 2002.
40. Levy MN, Pappano AJ. Cardiovascular Physiology, 9th ed. Philadelphia, PA: Mosby Elsevier; 2007.
41. Opie LH. Heart Physiology: From Cell to Circulation, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
42. Pypendop BH, Verstegen JP. Hemodynamic effects of medetomidine in the dog: a dose titration study. Vet Surg 1998; 27: 612-622.
43. Gomez De Segura IA, Vazquez Moreno-Planas I, Benito J, Galiano A, De Miguel E. Electrophysiologic cardiac effects of the new local anesthetic IQB-9302 and of bupivacaine in the anesthetised dog. Acta Anaesthesiol Scand 2002; 46: 666-673.
44. Beckman KJ, Parker RB, Hariman RJ, Gallastegui JL, Javaid JI, Bauman JL. Hemodynamic and electrophysiological actions of cocaine. Effects of sodium bicarbonate as an antidote in dogs. Circulation 1991; 83: 1799-1807.
45. Bicer S, Nakayama T, Hamlin RL. Effects of chronic oral amiodarone on left ventricular function, ECGs, serum chemistries, and exercise tolerance in healthy dogs. J Vet Intern Med 2002; 16: 247-540.
46. Lee JD, Tajimi T, Patritti J, Ross J Jr. Preload reserve and mechanisms of afterload mismatch in normal conscious dog. Am J Physiol 1986; 250 (3 Pt 2): H464-H473.
47. Boon JA. Manual of Veterinary Echocardiology. Philadelphia: Lippincott Williams & Wilkins; 1998.
48. Kohn DF, Wixson SK, White WJ, Benson GJ. Anesthesia and Analgesia in Laboratory Animals. San Diego, CA: Academic Press; 1997.
49. Muir WW. III, Hubbell JAE, Skarda RT, Bednarski RM. Handbook of Veterinary Anesthesia, 3rd ed. St Louis, MO: Mosby; 2000.
50. Riley DC, Schmeling WT, al-Wathiqui MH, Kampine JP, Warltier DC. Prolongation of the QT interval by volatile anesthetics in chronically instrumented dogs. Anesth Analg 1988; 67: 741-749.
51. Gallagher JD. Effects of halothane and quinidine on intracardiac conduction and QTc interval in pentobarbital-anesthetized dogs. Anesth Analg 1992; 75: 688-695.
52. Shimizu W, McMahon B, Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol 1999; 10: 154-164.
53. Takahara A, Sugiyama A, Satoh Y, Wang K, Honsho S, Hashimoto K. Halothane sensitizes the canine heart to pharmacological I Kr blockade. Eur J Pharmacol 2005; 507: 169-177.
54. Shimosato S, Etsten BE. Effect of anesthetic drugs on the heart: a critical review of myocardial contractility and its relationship to hemodynamics. Clin Anesth 1969; 3: 17-72.
55. Picker O, Scheeren TWL, Arndt JO. Inhalation anaesthetics increase heart rate by decreasing cardiac vagal activity in dogs. Br J Anaesth 2001; 87: 748-754.
56. Picker O, Schindler A, Scheeren TW. Accuracy and reproducibility of long-term implanted transit-time ultrasound flow probes in dogs. Intensive Care Med 2000; 26: 601-607.
57. www.dissdata.com.
58. Data Sciences International (www.datasci.com).
59. www.transonic.com.
60. Emka Technologies (www.emkatech.com).
61. www.vivometrics.com.
62. Buxco Electronics, Inc. (www.buxco.com).
63. Data Integrated Scientific Systems (www.itstelemetry.com).
64. LDS Test and Measurement (PoNeMah; http://www.lds-group.com).
65. Modular Instruments Inc. (www.mi2.com).
66. Notocord Systems (www.notocord.com).
67. Miura T, Miyazaki S, Guth BD, Indolfi C, Ross J Jr. Heart rate and force-frequency effects on diastolic function of the left ventricle in exercising dogs. Circulation 1994; 89: 2361-2368.
68. Kingma JG Jr, Armour JA, Rouleau JR. Left ventricular intramyocardial pressure determination using two different solid-state micromanometric pressure sensors. Can J Physiol Pharmacol 1996; 74 (6): 701-705.
69. Hamlin B, Guth B, Sarazan D, Picker O, Schindler A, Scheeren TW. Accuracy and reproducibility of long-term implanted transit-time ultrasound flow probes in dogs. Intensive Care Med 2000; 26: 601-607.
70. Hamlin RL, Nakayama T, Nakayama H, Carnes CA. Effects of changing heart rate on electrophysiological and hemodynamic function in the dog. Life Sci 2003; 72: 1919-1930.
71. Oyama MA, Sisson DD, Bulmer BJ, Constable PD. Echocardiographic estimation of mean left atrial pressure in a canine model of acute mitral valve insufficiency. J Vet Intern Med 2004; 18: 667-672.
72. Goldberger JJ, Kadish AH, Johnson D, Qi X. New technique for vagal nerve stimulation. J Neurosci Methods 1999; 91: 109-114.
73. Bass AS, Robie NW. Stereoselectivity of S-and R-sulpiride for pre-and postsynaptic dopamine receptors in the canine kidney. J Pharmacol Exp Ther 1984; 229: 67-71.
74. Bass AS, Murphy MB, Kohli JD, Goldberg LI. Potentiation by dopexamine of the cardiac responses to circulating and neuronally released norepinephrine: a possible mechanism for the therapeutic effects of the drug. J Cardiovasc Pharmacol 1989; 13: 667-671.
75. Nolan ER, Feng MR, Koup JR, Liu J, Turluck D, Zhang Y, Paulissen JB, Olivier NB, Miller T, Bailie M/B. A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic AV node - ablated, His bundle-paced dog. J Pharmacol Toxicol Methods 2006; 53: 1-10.
76. Toshida N, Hirao K, Yamamoto N, Tanaka M, Suzuki F, Isobe M. Ventricular echo beats and retrograde atrioventricular nodal exits in the dog heart: multiplicity in their electrophysiologic and anatomic characteristics. J Cardiovasc Electrophysiol 2001; 12: 1256-1264.
77. Smith DA, van de Waterbeemd, Walker DK. Pharmacokinetics and Metabolism in Drug Design, 2nd ed. Weinheim: Wiley-VCH; 2006.
78. Schoenwald RD, ed. Pharmacokinetics in Drug Discovery and Development. Boca Raton, FL: CRC Press; 2002.
79. Boroujerdi M. Pharmacokinetics: Principles and Applications. New York: McGraw-Hill Medical Publications Division; 2001.
80. Markert M, Klumpp A, Trautmann T, Guth B. A novel propellant-free inhalation drug delivery system for cardiovascular drug safety evaluation in conscious dogs. J Pharmacol Toxicol Methods 2004; 50: 109-119.
81. Petruska JM, Beattie JG, Stuart BO, Pai S, Walters KM, Banks CM, Lulham GW, Mirro EJ. Cardiovascular effects after inhalation of large doses of albuterol dry powder in rats, monkeys, and dogs: a species comparison. Fundam Appl Toxicol 1997; 40: 52-62.
82. Gad SC. Statistics and Experimental Design for Toxicologists and Pharmacologists, 4th ed. Boca Raton, FL: CRC Press; 2005.
83. Jones B, Kenward MG. Design and Analysis of Cross-over Trials. London: Chapman & Hall; 1989.
84. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design, 3rd ed. New York: McGraw Hill; 1991.
85. Snedecor GW, Cochran WG. Statistical Methods, 6th ed. Ames: Iowa State University Press; 1967.
86. Detweiler DK. Electrocardiographic monitoring in toxicological studies: principles and interpretations. Adv Exp Med Biol 1983; 161: 579-607.
87. Tilley LP, Burtnick NL. ECG for the Small Animal Practitioner. Jackson WY: Teton NewMedia; 1999.
88. Hanton G, Rabemampianina Y. The electrocardiogram of the beagle dog: reference values and effect of sex, genetic strain, body position and heart rate. Lab Anim 2006; 40: 123-136.
89. Roden DM, Anderson ME. Proarrhythmia. In Starke FK, Ed., Handbook of Experimental Pharmacology, Vol. 171. New York; Springer 2006, pp 73-97. 7.
90. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR. Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15: 475-495.
91. Soloviev MV, Hamlin RL, Shellhammer LJ, Barrett RM, Wally RA, Birchmeier PA, Schaefer GJ. Variations in hemodynamic parameters and ECG in healthy, conscious, freely moving telemetrized beagle dogs. Cardiovasc Toxicol 2006; 6: 51-62.
92. Watanabe H, Miyazaki H. A new approach to correct the QT interval for changes in heart rate using a nonparametric regression model in beagle dogs. J Pharmacol Toxicol Methods 2006; 53: 234-241.
93. Tattersall ML, Dymond M, Hammond T, Valentin JP. Correction of QT values to allow for increases in heart rate in conscious beagle dogs in toxicology assessment. J Pharmacol Toxicol Methods 2006; 53: 11-19.
94. Batey AJ, Doe CP. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs. J Pharmacol Toxicol Methods 2002; 48: 11-19.
95. Raunig D, Depasquale MJ, Huang CH, Winslow R, Fossa AA. Statistical analysis of QT interval as a function of changes in RR interval in the conscious dog. J Pharmacol Toxicol Methods 2001; 46: 1-11.
96. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Safety 2001; 24: 323-351.
97. Fridericia LS. Die systolendauer im elektrokardogramm bei normalen menchen und bei Herzkranken. Acta Med Scand 1920; 53: 469-486.
98. Spence S, Soper K, Hoe CM, Coleman J. The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. Toxicol Sci 1998; 45: 247-258.
99. Osborne BE, Leach GDH. The beagle electrocardiogram. Fundam Cosmet Toxicol 1971; 9: 2857-2864.
100. Fossa AA, Wisialowski T, Crimin K. QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization. J Pharmacol Exp Ther 2006; 316: 498-506.
101. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-370.
102. Dessertenne F. La tachycardia ventriculaire a deux foyers opposes variables. Arch Mal Coeur 1996; 59: 263-272.
103. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between and inherited and acquired cardiac arrhythmia: HERG encodes the iKr potassium channel. Cell 1995; 81: 299-307.
104. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995; 269: 92-95.
105. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basic for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803.
106. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT. Properties of HERG channels stably expressed in HEK293 cells studied at physiological temperature. Biophys J 1998; 74: 230-241.
107. Walker BD, Valenzuela SM, Singleton CB, Tie H, Bursill JA, Wyse KR, Qiu MR, Breit SN, Campbell TJ. Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate. Br J Pharmacol 1999; 127: 243-251.
108. Witchel HJ, Milnes JT, Mitcheson JS, Hancox JC. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods 2002; 48: 65-80.
109. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004; 50: 93-101.
110. Guo L, Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods 2005; 52 (1): 123-135.
111. Gintant GA, Su Z, Martin RL, Cox BF. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. J Toxicol Pathol 2006; 34: 81-90.
112. Yao J-A, Du X, Lu D, Baker RL, Daharsh E, Atterson P. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J Pharmacol Toxicol Methods 2005; 52: 146-153.
113. Herron W, Towers C, Templeton A. Experiences in method development for the analysis of in vitro study solutions for content. J Pharmacol Toxicol Methods 2004; 49: 211-216.
114. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Pelethorpe Sl, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
115. Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS, Cox BF, Gintant GA. The [ 3 H] dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K + ] o. J Pharmacol Toxicol Methods 2004; 50: 187-199.
116. Chaudhary KW, O'Neal JM, Mo Z-L, Fermini B, Gallavan RH, Bahinski A. Evaluation of the rubidium efflux assay for preclinical identification of hERG blockade. Assay Drug Dev Technol 2006; 4 (1): 73-82.
117. Baxter DF, Kirk M, Garcia AF, Raimondi A, Holmqvist MH, Flint KK, Bojanic D, Distefano PS, Curtis Rl, Xie Y. A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J Biomol Screen 2002; 7 (1): 79-85.
118. Bril A, Gout B, Bonhomme M, Landais L, Faivre J, Linee P, Poyser RH, Ruffolo RR Jr. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 1996; 509: 129-137.
119. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identifi- cation of the verapamil binding domain to HERG potassium channels. Circ Res 1999; 84: 989-998.
120. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. J Cardiovasc Pharmacol 2004; 43: 369-379.
121. Ficker El, Kuryshev YA, Dennis AT, Oberjero-Paz C, Wang L, Hawryluk P, Wible BA, Brown AM. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66: 33-44.
122. Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2004; 109: 26-29.
123. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds Wl, Rampe D. Pentamidine-induced long QT syndrome and block of HERG trafficking. J Pharmacol Exp Ther 2005; 312 (1): 316-323.
124. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, Zhou J. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 2005; 145 (1): 15-23.
125. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. HERG-lite: a novel comprehensive high throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005; 52 (1): 136-145.
126. Glaaser IW, Kass RS, Clancy CE. Mechanisms of genetic arrhythmias: from DNA to ECG. Prog Cardiovasc Dis 2003; 46 (3): 259-270.
127. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 2005; 115 (8): 2025-2032.
128. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 2006; 259: 59-69.
129. Franz MR. Current status of monophasic action potential recording: theories measurements and interpretations. Cardiovasc Res 1999; 41: 25-40.
130. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia but APD prolongation is antiarrhythmic. Circulation 2001; 103: 2004-2013.
131. Strauss HC, Bigger JT Jr, Hoffman BF. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 1970; 26 (6): 661-678.
132. Sosunov EA, Anyukhovsky EP, Rosen MR. Effects of quinidine on repolarization in canine epicardium midmyocardium, and endocardium. I. In vitro study. Circulation 1997; 96: 4011-4018.
133. Wang L, Feng Z-P, Kondo CS, Sheldon RS, Duff HJ. Developmental changes in the delayes rectifier K+ channels in mouse heart. Circ Res 1996; 79: 79-85.
134. Liu GX, Zhou J, Nattel S, Koren G. Single-channel recordings of a rapid delayed rectifier current in adult mouse ventricular myocytes; basic properties and effects of divalent cations. J Physiol (London.) 2004; 556 (2): 401-413.
135. Wymore RS, Gintant GA, Wymore RT, Dixon JE, McKinnon D, Cohen IS. Tissue and species distribution of mRNA for the iKr-like K + channel, erg. Circ Res 1997; 80: 261-268.
136. McDermott JS, Salmen HJ, Cox BF, Gintant GA. Importance of species selection in arrhythmogenic models of QT interval prolongation. Antimicrob Agents Chemother 2002; 46 (3): 938-939.
137. January CT, Riddle JM. Early afterdepolarizations: mechansim of induction and block. A role for L-type Ca2+ current. Circ Res 1999; 64 (5): 977-990.
138. Lu HR, Vlaminckx E, Van Ammel K, De Clerck F. Drug-induced long QT in isolated rabbit Purkinje fibers; importance of action potential duration, triangulation and early afterdepolarizations. Eur J Pharmacol 2002; 452 (2): 183-192.
139. Hondeghem LM. TRIad; foundation for proarrhythmia (triangulation, reverse use dependence and instability). Novartis Found Symp 2005; 266: 235-244.
140. Brugada R, Hong K, Cordeiro JM, Dumaine R. Short QT syndrome. C MAJ 2005; 173 (11): 1349-1354
141. Horn R, Marty A. Muscarinic activation of ionic currents measured by a new whole-cell recording method. J Gen Physiol 1988; 92: 145-159.
142. Zaniboni M, Pollard AE, Yang L, Spitzer KW. Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. Am J Physiol Heart Circ Physiol 2000; 278 (3): H677-H687.
143. Sawanobori T, Adaniya H, Namiki T, Hiraoka M. Rate-dependent effects of sematilide on action potential duration in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1994; 271 (1): 302-310.
144. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr, Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995; 76: 110-119.
145. Gintant GA. Azimilide causes reverse rate-dependent block while reducing both components of delayed rectifier current in canine ventricular myocytes. J Cardiovasc Pharmacol 1998; 31: 945-953.
146. Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (IKr) channel. J Cardiovasc Electrophysiol 2004; 15: 1302-1309.
147. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 2001; 37: 607-618.
148. Lu HR, Vlaminckx E, Teisman A, Gallacher DJ. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit. J Pharmacol Toxicol Methods 2005; 52 (1): 90-105.
149. Varro A, Nakaya Y, Elharrar V, Surawicz B. The effects of amiodarone on repolarization and refractoriness of cardiac fibers. Eur J Pharmacol 1988; 154 (1): 11-18.
150. Kii Y, Hayashi S, Tabo M, et al. QT PRODACT. Evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles. J Pharmacol Sci 2006; 99 (5): 449-457.
151. Yan G-X, Shimizu W, Antzelevitch C. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 1998; 98: 1921-1927.
152. Yan G-X, Rials SJ, Wu Y, Liu T, Xu X, Marinchak RA, Kowey PR. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am J Physiol Heart Circ Physiol 2001; 281: H1968-H1975.
153. Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsades de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108: 1027-1033.
154. Yan G-X, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR. Phase 2 early afterdepolarizations as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome. Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001; 103: 2851-2856.
155. Sutherland FJ, Hearse DJ. The isolated blood and perfusion fluid perfused heart. Pharmacol Res 2000; 41 (6): 613-627.
156. Hondeghem LM, Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use-dependence, and instability. J Cardiovasc Pharmacol 2003; 41: 14-24.
157. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005; 2: 758-772.
158. Hamlin RL, Cruze CA, Mittelstadt SW, Kijtawornrat A, Keene BW, Roche BM, Takayama T, Nakayama H, Hamlin DM, Arnold T. Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. J Pharmacol Toxicol Methods 2004; 49: 15-23.
159. Eckardt L, Haverkamp W, Mertens H, Johna R, Clague JR, Borggrefe M, Beirthardt G. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium d, l-sotalol, and erythromycin. J Cardiovasc Pharmacol 1998; 32: 425-434.
160. Johna R, Mertens H, Haverkamp W, Eckardt L, Niederboker T, Borggrefe M, Breithardt G, Clofilium in the isolated perfused rabbit heart: a new model to study proarrhythmia induced by class III antiarrhythmic drugs. Basic Res Cardiol 1998; 93: 127-135.
161. Akoun GM, Milleron BJ, Mayaund CM, Francois TJ. Natural history of drug-induced pneumonitis. In Akoun GM, White PJ, Eds. Drug Induced Disorders, Vol. 3. Elsevier Scientific Publishers; 1989, pp 3-9.
162. Rosenow EC, Myers JL, Swensen SJ, Pisani RJ. Drug induced pulmonary disease: an update. Chest 1992; 102: 239-250.
163. Eldridge FL, Millhorn DE. Central regulation of respiration by endogenous neurotransmitters and neuromodulators. Annu Rev Physiol 1981; 43: 121-135.
164. Mueller RA, Lundberg DBA, Breese GR, Hedner J, Hedner T, Jonason J. The neuropharmacology of respiratory control. Pharmacol Rev 1982; 34: 255-285.
165. Heymans C. Action of drugs on carotid body and sinus. Pharmacol Rev 1955; 7: 119-142.
166. Heymans C, Neil E. The effects of drugs on chemoreceptors. In Heymans C, Neil E, eds. Reflexogenic Areas of the Cardiovascular System. London: Churchill Ltd; 1958; pp 192-199.
167. Sant'Ambrogio G. Nervous receptors of the tracheobronchial tree. Annu Rev Physiol 1987; 49: 611-627.
168. Phillipson EA. Disorders in the control of breathing: hypoventilation syndromes. In Murray JF, Nadal JA, eds. Textbook of Respiratory Medicine. Philadelphia: Saunders; 1988, pp 1831-1840.
169. Cherniack NS. Disorders in the control of breathing: hyperventilation syndromes. In Murray JF, Nadal JA, eds. Textbook of Respiratory Medicine. Philadelphia: Saunders; 1988, pp 1861-1866.
170. Laffey JG. Kavavagh BP. Hypocapnia. N Engl J Med 2002; 347 (1): 43-53.
171. Boggs DF. Comparative control of respiration. In Parent RA, ed. Comparative Biology of the Normal Lung, Vol I. Boca Raton FL: CRC Press; 1992, pp 309-350.
172. Keats AS. The effects of drugs on respiration in man. Annu Rev Pharmacol Toxicol 1985; 25: 41-65.
173. McCarthy DS. Airflow obstruction. In Kryger MH, eds. Pathophysiology of Respiration. Hoboken, NJ: Wiley; 1981, pp 7-42.
174. Rochester DF, Arora NS. Respiratory muscle failure. Med Clin Studies North Am 1983; 67: 573-597.
175. Milic-Emili J. Recent advances in clinical assessment of control of breathing. Lung 1982; 160: 1-17.
176. Warren CPW. Lung restriction. In Kryger MH, ed. Pathophysiology of Respiration. Hoboken, NJ: Wiley; 1981, pp 43-69.
177. Drorbaugh JE, Fenn WO. A barometric method for measuring ventilation in newborn infants. Pediatrics 1955; 16: 81-86.
178. Jacky JP. Barometric measurement of tidal volume: effects of pattern and nasal temperature . J Appl Physiol Respir Environ Exere Physiol 1980; 49 (2): 319-325.
179. Zimmerman PV, Connellan SJ, Middleton HC, Tabona MV, Goldman MD, Pride N. Postural changes in rib cage and abdominal volume-motion coefficients and their effect on the calibration of a respiratory inductance plethysmograph. Am Rev Respir Dis 1983; 127: 209-214.
180. Murphy DJ, Joran ME, Renninger JE. Effects of adenosine agonists and antagonists on pulmonary ventilation in conscious rats. Gen Pharmacol 1993; 24 (4): 943-954.
181. Murphy DJ, Joran ME, Grando JC. Microcapnometry: a non-invasive method for monitoring arterial CO 2 tension in conscious rats. Toxicol Methods 1994; 4 (3): 177-187.
182. Murphy DJ, Joran ME, Grando JC. A non-invasive method for distinguishing central from peripheral nervous system effects of respiratory depressant drugs in conscious rats. Gen Pharmacol 1995; 26 (3): 569-575.
183. Watchko JF, Standaert TA, Mayock DE, Twiggs G, Woodrum DE. Ventilatory failure during loaded breathing: the role of central neural drive. J Appl Physiol 1988; 65 (1): 249-255.
184. Nuzzo PF, Anton WR. Practical applications of capnography. Respir Therapy 1986; 16: 12-17.
185. Lucke JN, Hall GM, Lister D. Porcine malignant hyperthermia I: metabolic and physiologic changes. Br J Anesthesiol 1976; 48: 297-304.
186. Becklake M, Crapo RO. American Thoracic Society Statement: Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
187. Diamond L, O'Donnell M. Pulmonary mechanics in normal rats. J Appl Physiol Respir Environ Exerc Physiol 1977; 43: 942-948.
188. Mauderly JL. Effect of inhaled toxicants on pulmonary function. In McClellan RO, Henderson RF, eds. Concepts in Inhalation Toxicology. New York: Hemisphere Publishing; 1989, pp 347-401.
189. Amdur MO, Mead J. Mechanics of respiration in unanesthetized guinea pigs. Am J Physiol 1958; 192: 364-368.
190. O'Neil JJ, Raub JA. Pulmonary function testing in small laboratory animals. Environ Health Perspect 1984; 56: 11-22.
191. Mauderly JL. The influence of sex and age on the pulmonary function of the beagle dog. J Gerontol 1974; 29: 282-289.
192. Douglas JS, Dennis MW, Ridgeway P, Bouhuys A. Airway dilation and constriction in spontaneously breathing guinea pigs. J Pharmacol Exp Ther 1971; 180: 98-109.
193. Kruger JJ, Bain T, Patterson JL Jr. Elevation gradient of intrathoracic pressure. J Appl Physiol 1961; 16: 465-468.
194. Murphy DJ, Renninger JP, Gossett KA. A novel method for chronic measurement of pleural pressure in conscious rats. J Pharmacol Toxicol Methods 1998; 39: 137-141.
195. Murphy DJ, Renninger JP, Coatney RW. A novel method for chronic measurement of respiratory function in the conscious monkey. J Pharmacol Toxicol Methods 2001; 46: 13-20.
196. Pennock BE, Cox CP, Rogers RM, Cain WA, Wells JH. A noninvasive technique for measurement of changes in specific airway resistance. J Appl Physiol 1979; 46: 39-406.
197. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156: 766-775.
198. Lundblad LKA, Irvin CG, Adler A, Bates JHT. A re-evaluation of the validity of unrestrained plethysmography in mice. J Appl Physiol 2002; 93: 1198-1207.
199. Celli BR. American Thoracic Society Statement: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (5) Suppl:S78-S121.
200. Brown LK, Miller A. Full lung volumes: functional residual capacity, residual volume and total lung capacity. In Miller A, ed. Pulmonary Function Tests: A Guide for the Student and House Officer. New York: Grune & Stratton; 1987, pp 53-58.
201. King TKC. Measurement of functional residual capacity in the rat. J Appl Physiol 1966; 21: 233-236.
202. Palecek F. Measurement of ventilatory mechanics in the rat. J Appl Physiol 1969; 27: 149-156.
203. Smolders FDJ, Folgering HTh, Bernards JA. Ventilation estimated from efferent phrenic nerve activity in the paralyzed cat. Pflugers Arch 1975; 359: 157-169.
204. Chitravanshi VC, Sapru HN. Phrenic nerve responses to chemical stimulation of the sub regions of ventral medullary respiratory neuronal group in the rat. Brain Res 1999; 821: 443-460.
205. Syabbalo N. Assessment of respiratory muscle function and strength. Postgrad Med J 1998; 74: 208-215.
206. Borison HL. Central nervous system depressants: control-systems approach to respiratory depression. Pharmacol Ther B 1997; 3: 211-226.
207. Trenchard D, Gardner D, Guz A. Role of pulmonary vagal afferent nerve fibers in the development of rapid shallow breathing in lung inflammation. Clin Sci 1972; 42: 251-263.
208. Drazen JM. Physiological basis and interpretation of indices of pulmonary mechanics. Environ Health Perspect 1984; 56: 3-9.
209. Costa DL, Raub JA, Tepper JS. Comparative respiratory physiology of the lung. In Parent RA, ed. Comparative Biology of the Normal Lung, Vol I. Boca Raton, FL: CRC Press; 1992, pp 175-402.
210. Hakkinen PJ, Witschi HP. Animal models. In Witschi HP, Brain JD, eds. Handbook of Experimental Pharmacology, Vol 75. New York: Springer-Verlag; 1985, pp 95-114.
211. Anon. ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals. European Agency for the Evaluation of Medicinal Products. Evaluation of Medicines for Human Use. CPMP/ICH/539/00, London, 16 November 2000.
212. Porsolt RD, Lemaire M, Dürmüller N, Roux S. New perspectives in CNS safety pharmacology . Fundam Clin Pharmacol 2002; 16: 197-207.
213. Porsolt RD. Central nervous system (CNS) safety pharmacology studies. In Vogel GH, Hock FJ, Maas J, Mayer D. eds. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Heidelberg: Springer Verlag; 2006, pp 15-60.
214. Irwin S. Comprehensive behavioral assessment: a systematic quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968; 13: 222-257.
215. Mattson JL, Spencer PJ, Albee RR. A performance standard for clinical and functional observational battery examination of rats. J Am Coll Toxicol 1996; 15: 239-250.
216. Reiter LR, McPhail RC. Motor activity: a survey of methods with potential use in toxicity testing. Neurobehav Toxicol 1979; 1 (Suppl):53-66.
217. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in mice and rats. J Am Pharm Assoc 1957; 46: 208-209.
218. Porsolt RD, Picard S, Lacroix P. International safety pharmacology guidelines (ICH S7A and S7B): where do we go from here? Drug Dev Res 2005; 64: 83-89.
219. Krall E. Antiepileptic drug development: anticonvulsant drug screening. Epilepsia 1978; 19: 409-428.
220. Simon P, Chermat R, Doaré L, Bourin M, Farinotti R. Interactions impr é vues de divers psychotropes avec les effets du barbital et du pentobarbital chez la souris. J Pharmacol (Paris) 1982; 13: 241-252.
221. Bammer C. Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: a review and some new results. Neurosci Biobehav Rev 1982; 6: 247-296.
222. Glick SD, Zimmerberg D. Amnesic effects of scopolamine. Behav Biol 1972; 7: 2445-2454.
223. Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv 1981; 12: 239-260.
224. Olton DS. The radial maze as a tool in behavioral pharmacology. Physiol Behav 1986; 40: 793-797.
225. Dunnett SB, Evenden JL, Iversen SD. Delay-dependent short-term memory deficits in aged rats. Psychopharmacology 1988; 96: 174-180.
226. Porsolt RD, Roux S, Wettstein JG. Animal models of dementia. Drug Dev Res 1995; 35: 214-229.
227. Prendergast MA, Jackson WJ, Terry AV, Decker MW, Arneric SA, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in young-adult monkeys. Psychopharmacology 1998; 136: 50-58.
228. Bartus RT, Flicker C, Dean RL. Logical principles for the development of animal models of age-related memory impairments. In Crook T, Bartus RT, Ferris S, Gershon S, eds. Assessment in Psychopharmacology. Madison, WI: Mark Powley Associates; 1983, pp 263-299.
229. Dürmüller N, Guillaume P, Lacroix P, Porsolt RD, Moser P. Use of dog EEG in safety pharmacology. J Pharmacol Toxicol Methods 2007.
230. Itil TM. The discovery of psychotropic drugs by computer-analyzed cerebral bioelectrical potentials (CEEG). Drug Dev Res 1981; 1: 373-407.
231. Van Riezen H, Glatt AF. Introduction and history of the use of electroencephalography in animal drug studies. Neuropsychobiology 1993; 28: 118-125.
232. Jouvet M. Biogenic amines and the states of sleep. Science 1969; 163: 32-41.
233. Ruigt GSF, van Proosdij JN, van Delft AML. A large scale, high resolution automated system for rat sleep staging. EEG Clin Neurophysiol 1989; 73: 52-71.
234. Anon. Guideline on the Non-clinical Investigation of the Dependence Potential of Medicinal Products. EMEA/CHMP/SWP/94227/2004, London, 23 March 2006.
235. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Assess 2003; 70 (Suppl 3): S13-S40.
236. Balster RL. Drug abuse potential evaluation in animals. Br J Addiction 1991; 86: 1549-1558.
237. Goudie AJ, Harrison AA, Leathley MJ. Evidence for a dissociation between benzodiazepine withdrawal signs. NeuroReport 1993; 4: 295-299.
238. Lal H, ed. Discriminative Stimulus Properties of Drugs. New York: Plenum Press; 1977.
239. Gerak LR, France CP. Discriminative stimulus effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 1996; 276: 523-531.
240. Foltin RW, Fischman MW. The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. J Pharmacol Exp Ther 1992; 261: 623-632.
241. Schechter MD, Calcagnetti DJ. Trends in place preference conditioning, with a cross- indexed bibliography 1957-1991. Neurosci Biobehav Rev 1993; 17: 21-41.
242. Brady JV, Fischman MW. Assessment of drugs for dependence potential and abuse liability: an overview. In Seiden LS, Balster RL, eds. Behavioral Pharmacology: The Current Status. New York: Alan R Liss; 1985, pp 361-382.
243. Fozzard HA, Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: A new approach to the classification of antiarrhthmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851.